Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 17/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 16/20 | 0.48 |
| ▸ | AURKA | O14965 | 12/20 | 0.44 |
| ▸ | PLK1 | P53350 | 6/20 | 0.44 |
| ▸ | TTK | P33981 | 4/20 | 0.44 |
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | CCND3 | P30281 | 4/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 4/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.41 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548366 | 0.78 | CDK2 (0.57) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL2186347 | 0.75 | GRM5 (0.60) | CDK2CCNA2CCNA1 | |
| SCHEMBL2191200 | 0.75 | RIPK1 (0.49) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL2186516 | 0.74 | CDK2 (0.49) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL2187365 | 0.72 | CCNA2 (0.46) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL2189743 | 0.72 | GRM5 (0.55) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL7911087 | 0.71 | CDK2 (0.49) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL7903264 | 0.70 | GRM5 (0.63) | — | |
| SCHEMBL2540871 | 0.70 | CCNA2 (0.60) | CDK2CCNA2CCNA1AURKAPLK1 | |
| SCHEMBL2185127 | 0.67 | GRM5 (0.48) | CDK2CCNA2CCNA1AURKAPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | claimed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | claimed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | claimed |
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2011-10-27 | — | — | US | disclosed |
| EP-2346832-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | Glaxo Group Limited (GB) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010049366-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263588-A1 | TRICYCLIC COMPOUNDS AS GLUTAMATE RECEPTOR MODULATORS | GRM5, GRM1, GRM3 | CDK2 1514/4885CCNA2 4399/4885CCNA1 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.